Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by
malignant cells to support activated oncoproteins, including many cancer-associated …

For many decades classical anti-tumor therapies included chemotherapy, radiation and
surgery; however, in the last two decades, following the identification of the genomic drivers …

This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib,
which was recently approved by the US Food and Drug Administration for treatment of …

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

Adaptive resistance of myeloma to proteasome inhibition represents a clinical challenge,
whose biology is poorly understood. Proteasome mutations were implicated as underlying …

Proteolytic degradation is an essential cellular process which is primarily carried out by the
20S proteasome core particle (CP), a protease of 720 kDa and 28 individual subunits. As a …

Proteasome inhibition is a novel treatment for several hematological malignancies.
However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is an emerging …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

The IRE1α-XBP1 pathway, a key component of the endoplasmic reticulum (ER) stress
response, is considered to be a critical regulator for survival of multiple myeloma (MM) cells …

The bis-benzylidine piperidone RA190 covalently binds to cysteine 88 of ubiquitin receptor
RPN13 in the 19S regulatory particle and inhibits proteasome function, triggering rapid …